The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Merck & Co Inc

NYSE: MRK
Last

(U.S.) $49.03

Today's change+0.18 +0.37%
Updated February 12 4:01 PM EST. Delayed by at least 15 minutes.
 

Merck & Co Inc

NYSE: MRK
Last

(U.S.) $49.03

Today's change+0.18 +0.37%
Updated February 12 4:01 PM EST. Delayed by at least 15 minutes.

Merck & Co Inc up (U.S.)$0.18

Merck & Co Inc closed up Friday by (U.S.)$0.18 or 0.37% to (U.S.)$49.03. Over the last five days, shares have lost 0.71% and are down 7.18% for the last year to date. This security has underperformed the S&P 500 by 6.02% during the last year.

Key company metrics

  • Open(U.S.) $48.98
  • Previous close(U.S.) $48.85
  • High(U.S.) $49.11
  • Low(U.S.) $48.28
  • Bid / Ask-- / --
  • YTD % change-7.18%
  • Volume13,598,265
  • Average volume (10-day)14,548,284
  • Average volume (1-month)13,287,251
  • Average volume (3-month)11,640,123
  • 52-week range(U.S.) $45.69 to (U.S.) $61.70
  • Beta0.69
  • Trailing P/E31.36×
  • P/E 1 year forward13.24×
  • Forward PEG3.55×
  • Indicated annual dividend(U.S.) $1.84
  • Dividend yield3.75%
  • Trailing EPS(U.S.) $1.56
Updated February 12 4:01 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+11.29%

Based on its net profit margin of 11.29%, Merck & Co Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX2.43%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue39,49810,0739,7859,425
Total other revenue--------
Total revenue39,49810,0739,7859,425
Gross profit24,5646,3826,1365,961
Total cost of revenue14,9343,6913,6493,464
Total operating expense32,5707,8468,2397,989
Selling / general / administrative10,3132,4292,4712,338
Research & development6,7041,4831,6551,735
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)619243464452
Other operating expenses, total--------
Operating income6,9282,2271,5461,436
Interest income (expense), net non-operating---165-174-164
Gain (loss) on sale of assets--------
Other--------
Income before tax5,4012,3978071,381
Income after tax4,4591,831688958
Income tax, total942566119423
Net income4,4421,826687953
Total adjustments to net income--------
Net income before extra. items4,4421,826687953
Minority interest-17-5-1-5
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items4,4421,826687953
Inc. avail. to common incl. extra. items4,4421,826687953
Diluted net income4,4421,826687953
Dilution adjustment--------
Diluted weighted average shares2,8412,8362,8502,865
Diluted EPS excluding extraordinary itemsvalue per share1.560.640.240.33
Dividends per sharevalue per share1.800.450.450.45
Diluted normalized EPSvalue per share1.740.710.380.44